April 2026
1. ENWRIGHT JF 3RD, Tamburino AM, Tumkaya T, Lovatt D, et al
   Transcriptional Profiles of Somatostatin and Parvalbumin Interneuron Subtypes in the Human Dorsolateral Prefrontal Cortex: Implications for Schizophrenia.
   Am J Psychiatry. 2026 Apr 22:appiajp20250355. doi: 10.1176/appi.ajp.20250355.
   

   >> Share

   
   
2. KU SH, Stringfield SJ, Torregrossa MM, Sweet RA, et al
   Envisioning Cannabinoid CB1 Receptor Biased Signaling as a Therapeutic Target for Schizophrenia.
   Am J Psychiatry. 2026 Apr 17:appiajp20250886. doi: 10.1176/appi.ajp.20250886.
   

   >> Share

   
   
3. DE LAS CUEVAS C
   Beyond Symptom Thresholds: Toward a Clinically and Culturally Inclusive Definition of Relapse in Schizophrenia.
   Am J Psychiatry. 2026;183:269-270.
   

   >> Share

   
   
4. NICHOLSON RC, Choi UE, Mojtabai R, Thrul J, et al
   Association of Cannabis Use Disorder Versus Other Substance Use Disorders With Psychiatric Conditions: A Propensity-Matched Retrospective Cohort Analysis.
   Am J Psychiatry. 2026;183:260-268.
   

   >> Share

   
   March 2026
5. MARDER SR
   Finding a Medication for Negative Symptoms in Schizophrenia: Why So Many Failures?
   Am J Psychiatry. 2026;183:154-155.
   

   >> Share

   
   
6. MYUNG W, Ahn Y, Kim J, Won HH, et al
   Targeted Therapeutic Intervention for Problematic Alcohol Use, Comorbid Depressive Disorder, and Schizophrenia: Response to Lawford and Norrie.
   Am J Psychiatry. 2026;183:216.
   

   >> Share

   
   
7. LI C, Sun P
   Overlooked Methodological Limitations in the Study of Grip Strength and Default Mode Network Connectivity in Early Psychosis.
   Am J Psychiatry. 2026;183:214.
   

   >> Share

   
   
8. KALIN NH
   Advances Relevant to Treating Bipolar Disorder, PTSD, and Schizophrenia.
   Am J Psychiatry. 2026;183:149-151.
   

   >> Share

   
   February 2026
9. KAUL I, Claxton A, Sauder C, Patel T, et al
   Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension Trial.
   Am J Psychiatry. 2026 Feb 4:appiajp20241186. doi: 10.1176/appi.ajp.20241186.
   

   >> Share

   
   
10. KALIN NH
    Neuroplasticity, Antipsychotic Efficacy, Schizophrenia Risk Reduction With Doxycycline Exposure, and Cannabis and Alcohol Use Interactions.
    Am J Psychiatry. 2026;183:87-89.
    

    >> Share

    
    December 2025
11. KELLNER CH
    Electroconvulsive Therapy (ECT) for Postpartum Psychosis: Treatment for a Medical Emergency.
    Am J Psychiatry. 2025;182:1093.
    

    >> Share

    
    
12. BERGINK V, Kamperman A, Robakis T
    Electroconvulsive Therapy (ECT) for Postpartum Psychosis: Treatment for a Medical Emergency: Response to Kellner.
    Am J Psychiatry. 2025;182:1094.
    

    >> Share

    
    November 2025
13. KANTROWITZ JT, Mayer MR, Choo TH, Liu K, et al
    Effect Size Deflation With Increasing Sample Size in Adjunctive Trials for Negative Symptoms in Schizophrenia: A Meta-Analysis and Meta-Regression Across Mechanisms of Action.
    Am J Psychiatry. 2025 Nov 19:appiajp20250034. doi: 10.1176/appi.ajp.20250034.
    

    >> Share

    
    
14. LANG U, Metsala J, Ramsay H, Boland F, et al
    Doxycycline Use in Adolescent Psychiatric Patients and Risk of Schizophrenia: An Emulated Target Trial.
    Am J Psychiatry. 2025 Nov 5:appiajp20240958. doi: 10.1176/appi.ajp.20240958.
    

    >> Share

    
    
15. KALIN NH
    Schizophrenia, Alcohol Use Disorder, and Stimulant Use Disorder.
    Am J Psychiatry. 2025;182:957-959.
    

    >> Share

    
    
16. YALCINBAS EA, Ajanaku B, Nelson ED, Garcia-Flores R, et al
    Transcriptomic Analysis of the Human Habenula in Schizophrenia.
    Am J Psychiatry. 2025;182:991-1006.
    

    >> Share

    
    
17. GUR RE
    Pathways to Psychosis: Factors Associated With Risk for Psychosis Spectrum Disorders.
    Am J Psychiatry. 2025;182:984-990.
    

    >> Share

    
    October 2025
18. ZHAO G, Sun Y, Zhang Y, Lu T, et al
    Efficacy and Tolerability of Seven Antipsychotic Drugs in Acutely Ill Patients With Schizophrenia: A Randomized, Multicenter, Assessor-Blinded Trial.
    Am J Psychiatry. 2025 Oct 29:appiajp20250111. doi: 10.1176/appi.ajp.20250111.
    

    >> Share

    
    
19. HOWES OD, Bukala BR, Chen EYH, Correll CU, et al
    Relapse in Schizophrenia: A Systematic Review of Criteria for Clinical Studies and International Consensus Guidelines to Improve Them.
    Am J Psychiatry. 2025 Oct 8:appiajp20241040. doi: 10.1176/appi.ajp.20241040.
    

    >> Share

    
    September 2025
20. KALIN NH
    Scientific Advances Relevant to Schizophrenia, Psychosis, and the Treatment of Methamphetamine Use Disorder.
    Am J Psychiatry. 2025;182:797-800.
    

    >> Share

    
    
21. HORAN WP, Harvey PD, Brannan SK
    Does Xanomeline/Trospium Have Unique Benefits for Cognitive Impairment Associated With Schizophrenia? Response to Tandon.
    Am J Psychiatry. 2025;182:878-879.
    

    >> Share

    
    
22. CASSIDY C, Wang Y, Abi-Dargham A
    Forging a Role for Iron in the Dopamine Dysfunction of Schizophrenia.
    Am J Psychiatry. 2025;182:804-806.
    

    >> Share

    
    
23. VANO LJ, McCutcheon RA, Sedlacik J, Kaar SJ, et al
    Reduced Brain Iron and Striatal Hyperdopaminergia in Schizophrenia: A Quantitative Susceptibility Mapping MRI and PET Study.
    Am J Psychiatry. 2025;182:830-839.
    

    >> Share

    
    
24. TANDON R
    Does Xanomeline/Trospium Have Unique Benefits for Cognitive Impairment Associated With Schizophrenia?
    Am J Psychiatry. 2025;182:878.
    

    >> Share

    
    
25. ANGLIN DM, Olfson M, van der Ven E, Oh H, et al
    Neighborhood Social Vulnerability and Racial Disparities in Schizophrenia Spectrum Disorder Prevalence.
    Am J Psychiatry. 2025;182:850-860.
    

    >> Share

    
    July 2025
26. AHN Y, Kim J, Jung K, Lee DJ, et al
    Relationship Between Problematic Alcohol Use and Various Psychiatric Disorders: A Genetically Informed Study.
    Am J Psychiatry. 2025;182:671-682.
    

    >> Share

    
    June 2025
27. WARD HB, Beermann A, Manzanarez Felix K, Narisetti L, et al
    Grip Strength as a Marker of Resting-State Network Integrity and Well-Being in Early Psychosis.
    Am J Psychiatry. 2025 Jun 25:appiajp20240780. doi: 10.1176/appi.ajp.20240780.
    

    >> Share

    
    
28. KALIN NH
    Depression, Inflammation, and Postpartum Psychosis.
    Am J Psychiatry. 2025;182:501-503.
    

    >> Share

    
    
29. DAZZAN P
    A Step Closer to Understanding Familial Risk for Postpartum Psychosis.
    Am J Psychiatry. 2025;182:504-505.
    

    >> Share

    
    May 2025
30. ZHANG L, Ivleva EI, Parker DA, Hill SK, et al
    Impact of Polygenic Interactions With Anticholinergic Burden on Cognition and Brain Structure in Psychosis Spectrum Disorders.
    Am J Psychiatry. 2025 May 28:appiajp20240709. doi: 10.1176/appi.ajp.20240709.
    

    >> Share

    
    
31. KEPINSKA AP, Robakis TK, Humphreys K, Liu X, et al
    Familial Risk of Postpartum Psychosis.
    Am J Psychiatry. 2025 May 19:appiajp20230576. doi: 10.1176/appi.ajp.20230576.
    

    >> Share

    
    April 2025
32. CHENGAPPA KNR, Gannon JM, Joshi YB
    A Call to Psychiatrists: Deprescription of Unnecessary Anticholinergic Medications in Schizophrenia Must Start Now.
    Am J Psychiatry. 2025;182:319-321.
    

    >> Share

    
    
33. PERLIS RH
    Targeting Schizophrenia.
    Am J Psychiatry. 2025;182:329-331.
    

    >> Share

    
    
34. ORHAN F, Malwade S, Khanlarkhani N, Gkogka A, et al
    Kynurenic Acid and Promotion of Activity-Dependent Synapse Elimination in Schizophrenia.
    Am J Psychiatry. 2025;182:389-400.
    

    >> Share

    
    
35. ZHOU L, Sommer IEC, Yang P, Sikirin L, et al
    What Do Four Decades of Research Tell Us About the Association Between Childhood Adversity and Psychosis: An Updated and Extended Multi-Level Meta-Analysis.
    Am J Psychiatry. 2025;182:360-372.
    

    >> Share

    
    
36. KALIN NH
    Psychotic Disorders and Schizophrenia: Treatment, Risk, Brain Alterations, and Mechanisms.
    Am J Psychiatry. 2025;182:313-315.
    

    >> Share

    
    
37. NEUFELD NH, Blumberger DM
    An Update on the Use of Neuromodulation Strategies in the Treatment of Schizophrenia.
    Am J Psychiatry. 2025;182:332-340.
    

    >> Share

    
    March 2025
38. CORLETT PR, Fraser KM
    20 Years of Aberrant Salience in Psychosis: What Have We Learned?
    Am J Psychiatry. 2025 Mar 26:appiajp20240556. doi: 10.1176/appi.ajp.20240556.
    

    >> Share

    
    
39. KALIN NH
    New Developments in the Treatment of Depression, OCD, and Schizophrenia.
    Am J Psychiatry. 2025;182:223-226.
    

    >> Share

    
    
40. JAVITT DC
    Xanomeline-Trospium Treatment of Cognitive Impairments of Schizophrenia: Hope for Some, or Hope for All?
    Am J Psychiatry. 2025;182:237-239.
    

    >> Share

    
    February 2025
41. OMLOR W, Rabe F, Fuchs S, Surbeck W, et al
    Estimating Multimodal Structural Brain Variability in Schizophrenia Spectrum Disorders: A Worldwide ENIGMA Study.
    Am J Psychiatry. 2025 Feb 26:appiajp20230806. doi: 10.1176/appi.ajp.20230806.
    

    >> Share

    
    
42. MANCINI V, Latreche C, Fanshawe JB, Varvari I, et al
    Anticholinergic Burden and Cognitive Function in Psychosis: A Systematic Review and Meta-Analysis.
    Am J Psychiatry. 2025 Feb 26:appiajp20240260. doi: 10.1176/appi.ajp.20240260.
    

    >> Share

    
    
43. TIIHONEN J, Tanskanen A, Solmi M, Rubio JM, et al
    Continuous Dopamine D(2) Receptor Blockade and Long-Term Outcome in First-Episode Schizophrenia.
    Am J Psychiatry. 2025 Feb 19:0. doi: 10.1176/appi.ajp.20240321.
    

    >> Share

    
    December 2024
44. HORAN WP, Sauder C, Harvey PD, Ramsay IS, et al
    The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials.
    Am J Psychiatry. 2024 Dec 11. doi: 10.1176/appi.ajp.20240076.
    

    >> Share

    
    October 2024
45. GALLUCCI J, Yu JC, Oliver LD, Nakua H, et al
    Neural Circuitry and Therapeutic Targeting of Depressive Symptoms in Schizophrenia Spectrum Disorders.
    Am J Psychiatry. 2024;181:910-919.
    

    >> Share

    
    
46. REILLY TJ, McCutcheon RA
    Menopausal Hormone Therapy for Women With Schizophrenia: What's Stopping Us?
    Am J Psychiatry. 2024;181:854-855.
    

    >> Share

    
    
47. KRAMER EN, Velicu V
    Aripiprazole Augmentation as a Treatment for Clozapine-Induced Weight Gain.
    Am J Psychiatry. 2024;181:935-936.
    

    >> Share

    
    
48. CHENGAPPA KNR, Cotes RO
    Clozapine's High Incidence of Ileus and Pneumonia Demand Better Clinical Strategies-How Do We Get There?
    Am J Psychiatry. 2024;181:851-853.
    

    >> Share

    
    
49. MCINTYRE RS, Kwan ATH, Rosenblat JD, Teopiz KM, et al
    Aripiprazole Augmentation as a Treatment for Clozapine-Induced Weight Gain: Response to Kramer and Velicu.
    Am J Psychiatry. 2024;181:936-937.
    

    >> Share

    
    
50. HWANG M, Brady R
    Neural Circuitry and Therapeutic Targeting of Depressive Symptoms in Schizophrenia Spectrum Disorders.
    Am J Psychiatry. 2024;181:858-860.
    

    >> Share

    
    
51. ARNSTEN AFT, Datta D
    Characterizing the Most Vulnerable Prefrontal Cortical Neurons in Schizophrenia.
    Am J Psychiatry. 2024;181:861-864.
    

    >> Share

    
    
52. TAMMINGA CA
    Psychosis Risk With Prescription Amphetamine.
    Am J Psychiatry. 2024;181:856-857.
    

    >> Share

    
    
53. KALIN NH
    Schizophrenia Spectrum Disorders and Psychosis.
    Am J Psychiatry. 2024;181:847-850.
    

    >> Share

    
    
54. LEUCHT S, Priller J, Davis JM
    Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application.
    Am J Psychiatry. 2024;181:865-878.
    

    >> Share

    
    
55. ARION D, Enwright JF 3rd, Gonzalez-Burgos G, Lewis DA, et al
    Cell Type-Specific Profiles and Developmental Trajectories of Transcriptomes in Primate Prefrontal Layer 3 Pyramidal Neurons: Implications for Schizophrenia.
    Am J Psychiatry. 2024;181:920-934.
    

    >> Share

    
    September 2024
56. PARTANEN JJ, Happola P, Kampe A, Ahola-Olli A, et al
    High Burden of Ileus and Pneumonia in Clozapine-Treated Individuals With Schizophrenia: A Finnish 25-Year Follow-Up Register Study.
    Am J Psychiatry. 2024 Sep 12:appiajp20230744. doi: 10.1176/appi.ajp.20230744.
    

    >> Share

    
    
57. MORAN LV, Skinner JP, Shinn AK, Nielsen K, et al
    Risk of Incident Psychosis and Mania With Prescription Amphetamines.
    Am J Psychiatry. 2024 Sep 12:appiajp20230329. doi: 10.1176/appi.ajp.20230329.
    

    >> Share

    
    
58. BRAND BA, Sommer IE, Gangadin SS, Tanskanen A, et al
    Real-World Effectiveness of Menopausal Hormone Therapy in Preventing Relapse in Women With Schizophrenia or Schizoaffective Disorder.
    Am J Psychiatry. 2024 Sep 12:appiajp20230850. doi: 10.1176/appi.ajp.20230850.
    

    >> Share

    
    July 2024
59. JONSSON L, Horbeck E, Primerano A, Song J, et al
    Association of Occupational Dysfunction and Hospital Admissions With Different Polygenic Profiles in Bipolar Disorder.
    Am J Psychiatry. 2024;181:620-629.
    

    >> Share

    
    June 2024
60. KURTZ MM
    Cognitive Remediation in Schizophrenia Spectrum Illness: Evidence for Treatment Persistence.
    Am J Psychiatry. 2024;181:471-473.
    

    >> Share

    
    
61. VANO LJ, Veronese M, McCutcheon RA, Howes OD, et al
    Neuromelanin-Sensitive MRI: A Biomarker for Treatment-Resistant Schizophrenia?
    Am J Psychiatry. 2024;181:468-470.
    

    >> Share

    
    
62. BRENNAND KJ
    Aligning Stem Cell Models and Postmortem Studies to Query Striatal Neurodevelopment in Schizophrenia.
    Am J Psychiatry. 2024;181:465-467.
    

    >> Share

    
    
63. BIRNBAUM R, Weinberger DR
    The Genesis of Schizophrenia: An Origin Story.
    Am J Psychiatry. 2024;181:482-492.
    

    >> Share

    
    
64. KALIN NH
    Advances in Understanding Schizophrenia, ADHD, and ASD.
    Am J Psychiatry. 2024;181:461-464.
    

    >> Share

    
    
65. TRAMAZZO S, Lian W, Ajnakina O, Carlson G, et al
    Long-Term Course of Remission and Recovery in Psychotic Disorders.
    Am J Psychiatry. 2024;181:532-540.
    

    >> Share

    
    May 2024
66. KANG J, Castro VM, Ripperger M, Venkatesh S, et al
    Genome-Wide Association Study of Treatment-Resistant Depression: Shared Biology With Metabolic Traits.
    Am J Psychiatry. 2024 May 15:appiajp20230247. doi: 10.1176/appi.ajp.20230247.
    

    >> Share

    
    April 2024
67. LIGHT GA, Swerdlow NR
    Predicting Conversion to Psychosis: What Lies Beyond the Biomarkers?
    Am J Psychiatry. 2024;181:272-274.
    

    >> Share

    
    March 2024
68. VAN DER PLUIJM M, Wengler K, Reijers PN, Cassidy CM, et al
    Neuromelanin-Sensitive MRI as Candidate Marker for Treatment Resistance in First-Episode Schizophrenia.
    Am J Psychiatry. 2024 Mar 13:appiajp20220780. doi: 10.1176/appi.ajp.20220780.
    

    >> Share

    
    
69. VITA A, Barlati S, Ceraso A, Nibbio G, et al
    Durability of Effects of Cognitive Remediation on Cognition and Psychosocial Functioning in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Am J Psychiatry. 2024 Mar 13:appiajp20230396. doi: 10.1176/appi.ajp.20230396.
    

    >> Share

    
    February 2024
70. HOU Y, Xia H, He T, Zhang B, et al
    N2 Responses in Youths With Psychosis Risk Syndrome and Their Association With Clinical Outcomes: A Cohort Follow-Up Study Based on the Three-Stimulus Visual Oddball Paradigm.
    Am J Psychiatry. 2024 Feb 29:appiajp20221013. doi: 10.1176/appi.ajp.20221013.
    

    >> Share

    
    
71. ROGNLI EB, Hoye A, Bramness JG
    Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention: Response to Zhu et al.
    Am J Psychiatry. 2024;181:168-169.
    

    >> Share

    
    
72. ZHU L, Ni T, Guan F
    Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention.
    Am J Psychiatry. 2024;181:168.
    

    >> Share

    
    November 2023
73. SAWADA T, Barbosa AR, Araujo B, McCord AE, et al
    Recapitulation of Perturbed Striatal Gene Expression Dynamics of Donor's Brains With Ventral Forebrain Organoids Derived From the Same Individuals With Schizophrenia.
    Am J Psychiatry. 2023 Nov 2:appiajp20220723. doi: 10.1176/appi.ajp.20220723.
    

    >> Share

    
    
74. KALIN NH
    New Insights Into Psychotic Disorders.
    Am J Psychiatry. 2023;180:779-781.
    

    >> Share

    
    
75. VAN DER VEN E, Susser E
    Structural Racism and Risk of Schizophrenia.
    Am J Psychiatry. 2023;180:782-784.
    

    >> Share

    
    
76. CANNON TD
    Predicting Conversion to Psychosis Using Machine Learning: Are We There Yet?
    Am J Psychiatry. 2023;180:789-791.
    

    >> Share

    
    
77. GOFF DC, Roffman J, Holt DJ
    Another Step Toward the Prediction of Antipsychotic Treatment Response Using Functional Connectivity.
    Am J Psychiatry. 2023;180:787-788.
    

    >> Share

    
    
78. FORSYTH JK, Bearden CE
    Rethinking the First Episode of Schizophrenia: Identifying Convergent Mechanisms During Development and Moving Toward Prediction.
    Am J Psychiatry. 2023;180:792-804.
    

    >> Share

    
    
79. STRAWBRIDGE RJ, Graham N
    Dissecting the Genetic Relationship Between Schizophrenia and Cardiovascular Disease.
    Am J Psychiatry. 2023;180:785-786.
    

    >> Share

    
    
80. JOSHI Y, Swerdlow N, Light G
    Points that Need Attention in Early Auditory Information Processing Research in Schizophrenia: Response to Lin and Hsieh.
    Am J Psychiatry. 2023;180:841-842.
    

    >> Share

    
    October 2023
81. SMUCNY J, Davidson I, Carter CS
    Are We There Yet? Predicting Conversion to Psychosis Using Machine Learning.
    Am J Psychiatry. 2023 Oct 4:appiajp20220973. doi: 10.1176/appi.ajp.20220973.
    

    >> Share

    
    September 2023
82. RODEVAND L, Rahman Z, Hindley GFL, Smeland OB, et al
    Characterizing the Shared Genetic Underpinnings of Schizophrenia and Cardiovascular Disease Risk Factors.
    Am J Psychiatry. 2023 Sep 27:appiajp20220660. doi: 10.1176/appi.ajp.20220660.
    

    >> Share

    
    
83. KUMAR K, Modenato C, Moreau C, Ching CRK, et al
    Subcortical Brain Alterations in Carriers of Genomic Copy Number Variants.
    Am J Psychiatry. 2023;180:685-698.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share